ACE2 is a type one transmembrane metallo carboxypeptidase with similarity to ACE. Heart, vessels, gut, kidney, respiratory organ, testicle, brain these are the organ in which ACE2 receptor is widely expressed. It acts as a key player in renin angiotensin system and serves as a target for the treatment of cardiovascular diseases. Angiotensin II, a compound with angiotensin converting enzyme (ACE) activity, regulates vascular tone, stimulates the development of proinflammatory cytokines, inhibits NFkappaB, enhances oxidant stress, and suppresses nitric oxide synthesis. Thus, angiotensin-II is basically pro-inflammatory, thus the ACE inhibitors and ARBs used as therapeutic agents will reverse this effect and will decrease inflammatory mediators. ACE inhibitors and the ARBs will decrease the renal damage of SARS COV nephropathy by reducing the macrophage infiltration. Current evidence does not prove any negative impact of ARB and ACEI on Covid-19. It is clear from the mechanism based evidences that the ACE inhibitors and the ARBs are having much more benefits and show evidence of efficacy and show promise in tackling all the three dangerous comorbidities of SARS COV 2 i.e. Heart disease, glomerular diseases and Diabetes Mellitus, discontinuing them only for the sake of small increase in ACE II expression will be unjustified. Those patients having the indications can be continued for ACE inhibitors and the ARBs with or without SARS COV 2.